Shares of OraSure Technologies (NASDAQ:OSUR) have been given an average rating of “Hold” by the six research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $21.50.
Several equities analysts recently issued reports on the stock. BidaskClub raised shares of OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Canaccord Genuity reissued a “buy” rating and set a $24.00 price target on shares of OraSure Technologies in a report on Friday, February 2nd. Zacks Investment Research raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, March 2nd.
In other OraSure Technologies news, Director Stephen S. Phd Tang sold 23,333 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the transaction, the director now directly owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Brian Smith sold 20,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $17.97, for a total transaction of $359,400.00. Following the completion of the transaction, the executive vice president now directly owns 28,075 shares of the company’s stock, valued at $504,507.75. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Elkfork Partners LLC bought a new position in shares of OraSure Technologies in the fourth quarter worth about $143,000. Oppenheimer Asset Management Inc. bought a new position in shares of OraSure Technologies in the third quarter worth about $186,000. Shikiar Asset Management Inc. bought a new position in shares of OraSure Technologies in the fourth quarter worth about $207,000. AMP Capital Investors Ltd bought a new position in shares of OraSure Technologies in the fourth quarter worth about $294,000. Finally, Quadrant Private Wealth Management LLC bought a new position in shares of OraSure Technologies in the fourth quarter worth about $300,000. 92.86% of the stock is owned by institutional investors.
NASDAQ:OSUR opened at $17.18 on Wednesday. The stock has a market cap of $1,079.22, a PE ratio of 33.69, a price-to-earnings-growth ratio of 4.93 and a beta of 1.65. OraSure Technologies has a 52 week low of $12.43 and a 52 week high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The firm had revenue of $52.00 million during the quarter, compared to the consensus estimate of $50.20 million. During the same period last year, the firm posted $0.13 EPS. The firm’s quarterly revenue was up 46.5% on a year-over-year basis. research analysts anticipate that OraSure Technologies will post 0.29 earnings per share for the current fiscal year.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/21/orasure-technologies-osur-receives-21-50-consensus-price-target-from-brokerages.html.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.